A randomized open label pivotal trial of SM-88 in third-line metastatic advanced pancreatic cancer patients
Latest Information Update: 26 Aug 2020
At a glance
- Drugs Racemetyrosine (Primary) ; Methoxsalen; Phenytoin; Sirolimus
- Indications Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Sponsors Tyme Technologies
- 21 Aug 2020 According to a Tyme Technologies media release, information about this trial will be presented at 2020 Cross-Border Healthcare Webinar Series.
- 04 Nov 2019 Status changed from planning to not yet recruiting, according to a Tyme Technologies media release.
- 04 Nov 2019 According to a Tyme Technologies media release, the company has received the Central Institutional Review Board approval and enrollment is expected to be underway in fourth quarter of 2019.